To amend title XVIII of the Social Security Act to extend eligibility for certain payment increases for biosimilar biological products under the Medicare program.
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™This bill proposes an amendment to title XVIII of the Social Security Act to extend the eligibility for certain payment increases for biosimilar biological products under the Medicare program. Biosimilar products are biologic medical products highly similar to already approved biological products, and the bill aims to continue financial incentives for their use within Medicare. The bill was introduced in the House during the 118th Congress but has no publicly available full text or detailed summary. Its latest action was referral to the Subcommittee on Health, and it is currently classified as failed or expired.
The bill sought to extend Medicare payment incentives for biosimilar biological products but did not advance beyond subcommittee referral and is now expired.
- Amends title XVIII of the Social Security Act, which governs Medicare.
- Focuses on extending payment increases for biosimilar biological products under Medicare.
- The bill was referred to the House Subcommittee on Health but did not progress further.
['Manufacturers and distributors of biosimilar biological products', 'Medicare beneficiaries who may have increased access to biosimilar treatments', 'Healthcare providers administering biosimilar products']
['Lack of publicly available full text limits detailed assessment of implementation and cost implications.', 'Potential budgetary impact on Medicare due to extended payment increases.', 'Oversight mechanisms for ensuring appropriate use of payment increases are not specified.']
The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health. It addresses Medicare payment policy related to biosimilar products, a topic of ongoing legislative interest given the role of biosimilars in healthcare cost management. The bill did not advance beyond subcommittee referral and is currently classified as failed or expired.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential increased adoption of biosimilar biological products due to extended payment incentives, possibly affecting market competition and healthcare costs.', 'Possible shifts in prescribing patterns by healthcare providers favoring biosimilars over original biologics.']
The absence of a full bill text and detailed summary restricts comprehensive analysis. Transparency would be improved by providing complete legislative language and fiscal impact assessments. Oversight considerations include monitoring the financial impact on Medicare and ensuring that extended payment increases are appropriately administered to support intended policy goals.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.